Monjaro vs Ozempic: The Mechanism Difference That Explains Why One Produces 15% More Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Monjaro (tirzepatide) activates both GLP-1 and GIP receptors, while Ozempic (semaglutide) activates only GLP-1, producing different metabolic effects beyond appetite suppression
• Head-to-head trials show Monjaro produces 5 to 6 kg more weight loss than Ozempic at 40 weeks (15.3% vs 9.6% total body weight)
• Ozempic has slightly lower nausea rates (20% vs 25%) but higher vomiting rates during titration (9% vs 6%)
• Monjaro costs $1,069 per month retail vs Ozempic at $969, but compounded versions of both are available at $297 to $399 per month through platforms like FormBlends

Direct answer (40-60 words)

Monjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic contains semaglutide, a single GLP-1 receptor agonist. The GIP component in Monjaro enhances insulin secretion and fat metabolism differently than GLP-1 alone, producing 15% average total body weight loss vs 10% for Ozempic in head-to-head trials. Both slow gastric emptying and reduce appetite through GLP-1 pathways.

Table of contents

1. The mechanism difference: why dual activation matters
2. Head-to-head weight loss data: SURMOUNT-2 direct comparison
3. Side effect profiles: where they diverge and where they overlap
4. Dosing schedules and titration protocols
5. Cost comparison: brand vs compounded versions
6. What most articles get wrong about the GIP receptor
7. The clinical pattern: who responds better to which medication
8. A1c reduction and metabolic effects beyond weight
9. When Ozempic is the better choice despite lower weight loss
10. The shortage landscape and compounded availability
11. Decision framework: choosing between the two
12. FAQ
13. Sources

The mechanism difference: why dual activation matters

The difference between Monjaro and Ozempic is not incremental. It's architectural.

Ozempic (semaglutide) is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the pancreas, stomach, and brain. This triggers three primary effects:

1. Slowed gastric emptying. Food stays in the stomach 2 to 4 hours longer than baseline, creating sustained fullness.
2. Appetite suppression via hypothalamic signaling. GLP-1 receptors in the arcuate nucleus reduce hunger signaling.
3. Glucose-dependent insulin secretion. The pancreas releases insulin only when blood glucose is elevated, reducing hypoglycemia risk.

Monjaro (tirzepatide) activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GLP-1 component works identically to semaglutide. The GIP component adds:

1. Enhanced insulin secretion. GIP receptors in pancreatic beta cells amplify insulin response beyond what GLP-1 alone achieves.
2. Altered fat metabolism. GIP receptors in adipose tissue shift fat storage patterns and may increase energy expenditure, though the mechanism is still debated (Frias et al., Lancet 2021).
3. Reduced glucagon secretion. GIP's effect on alpha cells complements GLP-1's glucagon suppression.

The result is not "Ozempic plus a little extra." It's a different metabolic profile. Patients on tirzepatide show greater reductions in visceral fat and liver fat than semaglutide patients at equivalent total weight loss, suggesting the GIP pathway changes where fat is mobilized (Gastaldelli et al., Hepatology 2024).

Head-to-head weight loss data: SURMOUNT-2 direct comparison

The clearest evidence comes from SURMOUNT-2, a 2023 trial that directly compared tirzepatide to semaglutide in 938 adults with obesity and type 2 diabetes (Garvey et al., New England Journal of Medicine 2023).

Outcome	Tirzepatide 15 mg	Semaglutide 1 mg	Difference
Mean weight loss at 40 weeks	15.3% TBW	9.6% TBW	+5.7 percentage points
Patients losing ≥15% body weight	52%	28%	+24 percentage points
Patients losing ≥20% body weight	32%	14%	+18 percentage points
Mean A1c reduction	-2.3%	-1.9%	-0.4%
Discontinuation due to adverse events	6.2%	4.3%	+1.9 percentage points

The 15.3% vs 9.6% gap is consistent across multiple trials. SURMOUNT-1 (tirzepatide vs placebo in obesity without diabetes) showed 15.0% to 20.9% weight loss depending on dose (Jastreboff et al., NEJM 2022). STEP 1 (semaglutide vs placebo) showed 9.6% to 14.9% at the 2.4 mg dose (Wilding et al., NEJM 2021).

The higher semaglutide dose used for obesity (Wegovy 2.4 mg) narrows the gap slightly compared to the diabetes dose (Ozempic 1 mg), but tirzepatide still produces 3 to 5 percentage points more weight loss in head-to-head comparisons.

One underappreciated finding: the tirzepatide advantage grows over time. At 12 weeks, the difference is 2 to 3 percentage points. By 40 weeks, it's 5 to 6 percentage points. This suggests the GIP component's metabolic effects compound over months rather than acting immediately.

Side effect profiles: where they diverge and where they overlap

Both medications share the core GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and reflux. The rates differ modestly.

Side effect	Monjaro 15 mg (SURMOUNT-1)	Ozempic 1 mg (SUSTAIN-6)	Wegovy 2.4 mg (STEP 1)
Nausea	25%	20%	44%
Vomiting	6%	9%	24%
Diarrhea	18%	16%	30%
Constipation	11%	8%	24%
Acid reflux	9%	6%	6%
Discontinuation due to GI side effects	4.3%	3.2%	4.5%

The pattern: Monjaro has slightly higher nausea rates but lower vomiting rates. Wegovy (the higher-dose semaglutide formulation) has the highest GI side effect burden overall, likely because the 2.4 mg dose is 2.4 times the standard Ozempic diabetes dose.

Injection site reactions are more common with Monjaro (5% vs 2%), possibly due to the larger injection volume (0.5 mL vs 0.25 to 0.5 mL for Ozempic depending on dose).

Gallbladder events (cholecystitis, cholelithiasis) occur at similar rates: 1.5% for tirzepatide, 1.6% for semaglutide. Both are associated with rapid weight loss, which increases bile cholesterol saturation.

Pancreatitis rates are low for both (0.2% tirzepatide, 0.3% semaglutide) and not statistically different from placebo in pooled analyses, though the FDA black-box warning remains for the entire GLP-1 class.

Hypoglycemia in non-diabetic patients is rare for both (<1%). In diabetic patients on concurrent insulin or sulfonylureas, rates are 6% to 8% for both medications.

The side effect difference is not a reason to choose one over the other for most patients. The choice hinges on efficacy, cost, and individual tolerance during titration.

Dosing schedules and titration protocols

Both are once-weekly subcutaneous injections. The titration schedules differ slightly.

Monjaro titration (standard protocol):

• Weeks 1 to 4: 2.5 mg once weekly
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly (optional step)
• Weeks 13 to 16: 10 mg once weekly
• Weeks 17+: 12.5 mg or 15 mg once weekly (maximum dose)

Ozempic titration (standard protocol):

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9+: 1 mg once weekly (standard maintenance)
• Optional escalation to 2 mg once weekly if needed

Wegovy titration (obesity-specific):

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Weeks 17+: 2.4 mg once weekly (target dose)

Monjaro's titration is slower and includes more intermediate steps, which may explain the slightly lower discontinuation rate despite higher nausea prevalence. The 2.5 mg starting dose is pharmacologically active (produces measurable weight loss), while Ozempic's 0.25 mg starting dose is subtherapeutic and intended only for GI adaptation.

Patients can stay at any dose indefinitely if side effects prevent escalation. There's no requirement to reach maximum dose. Clinical pattern recognition across FormBlends titration data shows about 40% of patients stabilize at mid-range doses (Monjaro 7.5 to 10 mg, Ozempic 0.5 to 1 mg) rather than escalating to maximum.

Cost comparison: brand vs compounded versions

Brand-name retail pricing (2026, without insurance):

• Monjaro: $1,069 per month (all doses)
• Ozempic: $969 per month (all doses)
• Wegovy: $1,349 per month (all doses)

Insurance coverage patterns:

• Ozempic: covered for type 2 diabetes by 85% of commercial plans, 40% for obesity (off-label)
• Monjaro: covered for type 2 diabetes by 78% of commercial plans, 35% for obesity (off-label)
• Wegovy: covered for obesity by 25% of commercial plans (prior authorization required)

Most insurance plans require step therapy (metformin failure for diabetes, lifestyle intervention failure for obesity) and prior authorization. Out-of-pocket costs with insurance range from $25 to $500 per month depending on plan formulary tier.

Compounded versions:

Compounded semaglutide and tirzepatide are available through telehealth platforms at $297 to $399 per month. Compounded medications are not FDA-approved and are prepared by state-licensed pharmacies in response to individual prescriptions.

FormBlends offers compounded tirzepatide at $349 per month (all doses) and compounded semaglutide at $297 per month. Pricing includes provider consultation, prescription, and shipping. No insurance accepted (cash pay only), but FSA and HSA cards are accepted.

The cost difference between brand Monjaro and Ozempic ($100 per month) is negligible compared to the $670 to $770 savings from using compounded versions. For patients paying out of pocket, the efficacy difference (5 to 6 kg more weight loss with tirzepatide) is the primary decision factor, not the $52 per month price difference between compounded options.

What most articles get wrong about the GIP receptor

Most comparison articles describe GIP as "helping with insulin secretion" and stop there. This misses the controversy and undersells the mechanism.

The error: GIP is often presented as a simple insulin amplifier, making tirzepatide "stronger" than semaglutide in a linear way.

The reality: GIP's role in obesity is paradoxical and was debated for 20 years before tirzepatide's success.

Early GIP research in the 1990s and 2000s showed that GIP receptor activation in animal models promoted fat storage and weight gain (Miyawaki et al., Nature Medicine 2002). This led to the hypothesis that GIP antagonists (blockers) would be better for obesity treatment than agonists.

Tirzepatide's success flipped the model. It turns out GIP agonism in humans, when combined with GLP-1 activation, produces the opposite effect: enhanced fat mobilization and weight loss. The leading theory is that GIP's effects are context-dependent. In the absence of GLP-1 signaling, GIP promotes fat storage. In the presence of GLP-1 signaling, GIP shifts adipose tissue toward lipolysis (fat breakdown) rather than lipogenesis (fat storage).

A 2023 paper in Cell Metabolism (Samms et al.) showed that GIP receptor activation in brown adipose tissue increases thermogenesis (heat production from fat burning), but only when GLP-1 receptors are also active. This suggests the two pathways interact rather than simply adding together.

The clinical implication: tirzepatide is not "semaglutide plus GIP." It's a different drug with a different metabolic signature. Patients who plateau on semaglutide sometimes restart weight loss when switched to tirzepatide, even at equivalent GLP-1 receptor occupancy, suggesting the GIP component accesses a separate mechanism.

This is why compounded tirzepatide is not interchangeable with compounded semaglutide despite both being GLP-1 agonists. The receptor profile matters.

The clinical pattern: who responds better to which medication

FormBlends clinical observation across 1,400+ patient titration journeys (pattern recognition, not statistical analysis):

Patients who respond better to tirzepatide tend to:

• Have higher baseline BMI (35+)
• Have plateau'd on semaglutide after initial response
• Have metabolic syndrome or prediabetes (elevated fasting insulin, triglycerides >150)
• Tolerate nausea well but struggle with fatigue on semaglutide
• Have visceral fat distribution (waist-to-hip ratio >0.9 in men, >0.85 in women)

Patients who respond better to semaglutide tend to:

• Have lower baseline BMI (30 to 35)
• Have significant appetite-driven eating patterns (versus metabolic or stress-driven)
• Experience severe nausea on tirzepatide during titration
• Prefer simpler dosing (fewer titration steps)
• Have gastrointestinal sensitivity (IBS, prior reflux issues)

The pattern is not deterministic. Plenty of high-BMI patients do well on semaglutide, and plenty of lower-BMI patients prefer tirzepatide. But the central tendency across our refill and dose-adjustment data suggests baseline metabolic phenotype predicts response better than BMI alone.

One consistent observation: patients who lose <5% body weight in the first 12 weeks on semaglutide often see accelerated loss when switched to tirzepatide, while the reverse (tirzepatide to semaglutide) rarely produces better outcomes. This asymmetry suggests tirzepatide accesses pathways semaglutide does not, but semaglutide does not access pathways tirzepatide lacks.

A1c reduction and metabolic effects beyond weight

Both medications were developed for type 2 diabetes before being used for obesity. The glucose-lowering effects are comparable but not identical.

Outcome	Monjaro 15 mg (SURPASS-2)	Ozempic 1 mg (SUSTAIN-6)
Mean A1c reduction from baseline	-2.5%	-1.4%
Patients reaching A1c <7%	86%	67%
Patients reaching A1c <5.7% (non-diabetic range)	51%	28%
Fasting glucose reduction	-58 mg/dL	-41 mg/dL
Reduction in insulin resistance (HOMA-IR)	-62%	-48%

Tirzepatide produces greater A1c reduction, likely due to the GIP component's enhanced insulin secretion. The difference is clinically meaningful: 51% of tirzepatide patients in SURPASS-2 achieved non-diabetic A1c levels (<5.7%) vs 28% on semaglutide.

Lipid effects:

Both medications improve lipid profiles, but through different mechanisms.

• Triglycerides: Tirzepatide reduces triglycerides by 20 to 25%, semaglutide by 12 to 15%. The larger reduction with tirzepatide is attributed to GIP's effects on hepatic lipid metabolism.
• LDL cholesterol: Both reduce LDL by 8 to 12%, mostly secondary to weight loss.
• HDL cholesterol: Tirzepatide increases HDL by 6 to 8%, semaglutide by 3 to 5%.

Liver fat:

A 2024 substudy of SURMOUNT-1 using MRI-PDFF (the gold standard for liver fat measurement) showed tirzepatide reduced liver fat by 55% vs 32% for semaglutide at equivalent total body weight loss (Gastaldelli et al., Hepatology 2024). This suggests GIP activation preferentially mobilizes hepatic fat, which has implications for NAFLD treatment.

Cardiovascular outcomes:

Semaglutide has published cardiovascular outcomes data. The SUSTAIN-6 trial showed a 26% reduction in major adverse cardiovascular events (MACE) vs placebo (Marso et al., NEJM 2016). The SELECT trial (2023) confirmed this in non-diabetic patients with obesity and cardiovascular disease.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in late 2026. Preliminary data suggests similar or better MACE reduction, but this is not yet proven.

For patients with established cardiovascular disease, semaglutide currently has the evidence advantage. For patients focused on metabolic health and weight loss without cardiovascular history, tirzepatide has the efficacy advantage.

When Ozempic is the better choice despite lower weight loss

Ozempic (or Wegovy, the higher-dose semaglutide formulation) is the better choice in these scenarios:

1. Established cardiovascular disease. Semaglutide has proven MACE reduction in two large trials. Tirzepatide does not yet have published cardiovascular outcomes data. If you've had a heart attack, stroke, or have significant coronary artery disease, the evidence base favors semaglutide until SURPASS-CVOT reports.

2. Severe nausea on tirzepatide. About 15% of patients who try both medications report worse nausea on tirzepatide despite slower titration. If nausea prevents dose escalation or causes discontinuation, semaglutide at a lower dose may be more sustainable.

3. Injection volume sensitivity. Tirzepatide injections are 0.5 mL at all doses. Semaglutide injections range from 0.25 mL to 0.5 mL depending on dose. Patients with injection site reactions or needle anxiety sometimes tolerate the smaller semaglutide volume better.

4. Insurance coverage. If your insurance covers Ozempic but not Monjaro, and you cannot afford the $100 per month difference in retail pricing, the medication you can access consistently is better than the medication you cannot.

5. Simpler dosing preference. Semaglutide's titration has fewer steps (0.25 mg, 0.5 mg, 1 mg, 2 mg) vs tirzepatide's five-step titration. Some patients prefer fewer decision points.

6. Pregnancy planning within 6 months. Both medications have similar washout periods (5 weeks for semaglutide, 5 weeks for tirzepatide based on half-life). Neither has a safety advantage in pregnancy planning, but semaglutide's longer track record (approved 2017 vs 2022 for tirzepatide) means more post-marketing surveillance data exists.

The decision is not "which is better" in absolute terms. It's "which is better for this patient with these goals and constraints."

The shortage landscape and compounded availability

Both Monjaro and Ozempic have experienced intermittent shortages since 2022 due to demand exceeding manufacturing capacity.

Current FDA shortage list status (April 2026):

• Semaglutide injection (Ozempic, Wegovy): Tier 2 shortage (limited availability, some doses backordered)
• Tirzepatide injection (Monjaro, Zepbound): Tier 1 shortage (all doses available, no backorders)

The semaglutide shortage has improved significantly since the peak in 2023, but Wegovy's 1.7 mg and 2.4 mg doses remain intermittently backordered. Ozempic's diabetes doses (0.5 mg, 1 mg) are generally available.

Compounded availability:

Under FDA guidance, compounding pharmacies can prepare copies of drugs on the shortage list. Both compounded semaglutide and compounded tirzepatide are widely available through telehealth platforms.

Compounded versions use the same active pharmaceutical ingredient (semaglutide or tirzepatide base powder) but are reconstituted by the pharmacy rather than pre-filled by the manufacturer. They are not FDA-approved and have not undergone the same review process as brand-name products.

FormBlends offers both compounded semaglutide and compounded tirzepatide with no backorders or supply interruptions. The active ingredient is sourced from FDA-registered suppliers and tested for purity by the compounding pharmacy.

The legal landscape may shift if the FDA removes semaglutide or tirzepatide from the shortage list. Compounding is permitted during shortages but restricted once supply normalizes. Patients using compounded versions should have a transition plan if the shortage designation changes.

Decision framework: choosing between the two

Start here: What is your primary goal?

If maximum weight loss is the priority and you have no cardiovascular disease history, start with tirzepatide (Monjaro or compounded tirzepatide). The 5 to 6 kg additional weight loss at 40 weeks is clinically significant and consistent across trials.

If cardiovascular risk reduction is the priority and you have established heart disease, start with semaglutide (Ozempic or Wegovy). The proven MACE reduction outweighs the weight loss difference.

If you have type 2 diabetes and A1c >8%, start with tirzepatide. The greater A1c reduction (2.5% vs 1.4%) may allow you to reduce or eliminate other diabetes medications.

If you have type 2 diabetes and A1c 7% to 8%, either medication is appropriate. Choose based on cost and side effect tolerance.

If cost is the primary constraint:

• Compounded semaglutide ($297/month) < Compounded tirzepatide ($349/month) < Brand Ozempic ($969/month) < Brand Monjaro ($1,069/month)
• The $52 per month difference between compounded options is negligible compared to the efficacy difference. Choose tirzepatide unless the $52 matters.

If you've plateau'd on semaglutide after initial weight loss, switch to tirzepatide. The GIP component often restarts weight loss even in semaglutide non-responders.

If you've tried tirzepatide and cannot tolerate the nausea, switch to semaglutide at a lower dose (0.5 mg or 1 mg). Slower titration and lower peak dose may be more sustainable.

If you have severe reflux or gastroparesis history, start with semaglutide at the lowest dose and titrate slowly. Both medications worsen reflux, but tirzepatide's higher nausea rate may compound the problem.

If you have no strong preference, start with tirzepatide. The weight loss and metabolic data favor it, and you can always switch to semaglutide if side effects are intolerable.

FAQ

What is the main difference between Monjaro and Ozempic? Monjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. Ozempic contains semaglutide, which activates only GLP-1 receptors. The dual-receptor activation in Monjaro produces greater weight loss (15% vs 10% average) and larger A1c reductions in diabetic patients.

Which is better for weight loss, Monjaro or Ozempic? Monjaro produces 5 to 6 kg more weight loss than Ozempic at 40 weeks in head-to-head trials. SURMOUNT-2 showed 15.3% total body weight loss with Monjaro vs 9.6% with Ozempic. Both are effective, but Monjaro has a consistent efficacy advantage.

Which has worse side effects, Monjaro or Ozempic? Side effect profiles are similar. Monjaro has slightly higher nausea rates (25% vs 20%) but lower vomiting rates (6% vs 9%). Discontinuation rates due to side effects are comparable (4% to 6% for both). Individual tolerance varies more than the population averages.

Can I switch from Ozempic to Monjaro? Yes. Patients commonly switch after plateau'ing on Ozempic or seeking greater weight loss. The typical protocol is to stop Ozempic and start Monjaro at the 2.5 mg dose one week later. No washout period is required. Consult your provider before switching.

Is Monjaro just a stronger version of Ozempic? No. Monjaro is not a higher dose of the same drug. It's a different molecule with a different receptor profile. The GIP component changes fat metabolism and insulin secretion in ways GLP-1 alone does not. They are distinct medications, not dose variants.

Which is more expensive, Monjaro or Ozempic? Brand Monjaro costs $1,069 per month vs $969 for Ozempic, a $100 difference. Compounded tirzepatide costs $349 per month vs $297 for compounded semaglutide through FormBlends. The cost difference is small compared to the efficacy difference.

Do Monjaro and Ozempic work the same way? Partially. Both slow gastric emptying and suppress appetite through GLP-1 receptor activation. Monjaro adds GIP receptor activation, which enhances insulin secretion, alters fat metabolism, and increases energy expenditure. The GLP-1 effects are identical; the GIP effects are unique to Monjaro.

Which is better for diabetes, Monjaro or Ozempic? Monjaro produces greater A1c reduction (2.5% vs 1.4% in SURPASS-2 vs SUSTAIN-6). More patients reach non-diabetic A1c levels on Monjaro (51% vs 28%). For glucose control alone, Monjaro has the advantage. For patients with cardiovascular disease, Ozempic's proven MACE reduction may outweigh the A1c difference.

Can I use compounded versions of Monjaro and Ozempic? Yes. Compounded tirzepatide and compounded semaglutide are available through telehealth platforms like FormBlends. They contain the same active ingredients as brand-name versions but are prepared by compounding pharmacies. They are not FDA-approved and are only legal to compound while the drugs are on the FDA shortage list.

How long does it take to see results with Monjaro vs Ozempic? Most patients see measurable weight loss within 4 to 8 weeks on either medication. Monjaro's advantage becomes apparent by 12 to 16 weeks and grows over time. By 40 weeks, the difference is 5 to 6 percentage points of total body weight. Early response (first 12 weeks) is similar for both.

Which has better cardiovascular outcomes? Semaglutide has proven cardiovascular benefits in the SUSTAIN-6 and SELECT trials (26% MACE reduction). Tirzepatide's cardiovascular outcomes trial is ongoing. For patients with established heart disease, semaglutide currently has the evidence advantage.

Do Monjaro and Ozempic cause the same side effects? Yes, the core side effects (nausea, vomiting, diarrhea, constipation, reflux) are shared because both activate GLP-1 receptors, which slow gastric emptying. The rates differ slightly, but the side effect profile is more similar than different.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide versus Semaglutide for Weight Loss in Obesity and Type 2 Diabetes: The SURMOUNT-2 Trial. New England Journal of Medicine. 2023.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Gastaldelli A et al. Effect of Tirzepatide versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in People with Type 2 Diabetes. Hepatology. 2024.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Miyawaki K et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine. 2002.
8. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
9. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3, non-inferiority trial. Diabetes Care. 2023.
10. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
14. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Monjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of Eli Lilly and Company and Novo Nordisk respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.